New stock news | Bao Feng Tang's Hong Kong IPO prospectus invalid
The Hong Kong stock prospectus submitted by Zhuhai Baofengtang Semiconductor Co., Ltd. on September 30, 2025, expired on March 30, 2026, after 6 months.
Zhuhai Baofengtang Semiconductor Co., Ltd. (referred to as Baofengtang) submitted its Hong Kong IPO prospectus on September 30, 2025, which expired after 6 months on March 30, 2026. When submitting the prospectus, CMSC International served as its exclusive sponsor.
The prospectus shows that Baofengtang is a manufacturer of plasma processing equipment, specializing in the research and development, manufacturing, and sales of plasma processing equipment used in high-tech electronic fields such as PCB and semiconductor manufacturing. Its business covers mainland China, Southeast Asia, North America, and Europe.
The company's equipment mainly includes plasma residue removal equipment widely used in PCB manufacturing, consumer electronics, and other industries; semiconductor dry etching equipment and dry etching equipment, as well as plasma residue removal equipment for semiconductor packaging; and loading and unloading equipment for plasma residue removal equipment.
Related Articles

BBSB INTL (08610) reported an annual net profit attributable to shareholders of 6.289 million Ringgit, a decrease of 75.99% year-on-year.

XINHUA LANDE (08106) releases its financial performance for the year 2025, with a net profit of 108.7 million yuan.

Yik Wo International (08659) announces financial performance for 2025. The attributable loss for the year is expected to be approximately 6.773 million yuan, a year-on-year change from profit to loss.
BBSB INTL (08610) reported an annual net profit attributable to shareholders of 6.289 million Ringgit, a decrease of 75.99% year-on-year.

XINHUA LANDE (08106) releases its financial performance for the year 2025, with a net profit of 108.7 million yuan.

Yik Wo International (08659) announces financial performance for 2025. The attributable loss for the year is expected to be approximately 6.773 million yuan, a year-on-year change from profit to loss.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


